Kairos Pharma, LTD.
KAPANYSEHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | |
|---|---|---|---|
| Revenue | — | — | — |
| Operating income | −$5.6M | −$2.3M | −$1.7M |
| Net income | −$5.4M | −$2.6M | −$1.8M |
| Total assets | $6.5M | $5.8M | $965,000 |
| Total liabilities | — | $992,000 | $3.0M |
| Equity | $6.3M | $4.8M | −$2.1M |
| EPS (diluted) | $-0.30 | $-0.23 | $-0.17 |
| Shares out. | 16.7M | 13.7M | 10.6M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- −85.9%
- Return on assets
- −83.3%
- Return on capital (ROCE)
- −87.9%
- Liabilities / assets
- —
- Debt / equity
- —
- Book value / share
- $0.38
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Accruals / assets
- −30.7%clean
- Piotroski F-Score
- 2/6weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 1 warning● 1 good- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Negative operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Kmissed a reporting deadline ↗Mar 28, 2025
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Armistice Capital, LlcPassive (13G)Aug 14, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Murali RamachandranOfficer — VP of Research and Development | Nov 25, 2024 | Buy | 200 | $1.59 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 121,325 | 1.0 | -3.5% |
| Apr 30, 2026 | 125,693 | 1.0 | -14.3% |
| Apr 15, 2026 | 146,646 | 2.2 | -37.9% |
| Mar 31, 2026 | 236,224 | 2.3 | +19.1% |
| Mar 13, 2026 | 198,425 | 1.0 | -84.4% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Other material eventMay 18, 2026
- Entered a material agreement · Other material eventMar 2, 2026
- Other material eventFeb 26, 2026
- Director / officer changeOct 15, 2025
- Entered a material agreement · Other material eventOct 7, 2025
- Other material eventSep 18, 2025
- Other material eventSep 11, 2025
- Other material eventSep 3, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.